Buprenorphine HCI Injection, 0.3 mg/mL, 1 mL Single Dose Vial (NDC 42023-179-01), packaged in 1 mL x 5 Single Dose Vials per carton (NDC 42023-179-05), Rx Only, Distributed by: Par Pharmaceuticals Companies, Inc., Spring Valley, NY 10977.
Published May 17, 2017 · Recall initiated: April 28, 2017
Summary
FDA records drug Class II recall D-0698-2017, published May 17, 2017 and initiated April 28, 2017. Recalling firm: PAR Sterile Products LLC; Status: Terminated; Reported quantity: 122,469 cartons; Lot: Lot #: 821102, 821103, Exp 01/18; 821104, 821106, 821107, Exp 02/18; 821108, Exp 03/18; 821884, 821885, Exp 07/18; 821886, 821887, Exp 08/18; 822767, Exp 09/18; 824183, Exp 10/18. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Crystallization: due to the presence of white, crystalline particulates, adhered to the side and bottom of the glass vials, which are comprised of principally dextrose and the buprenorphine active component.
What to do
Voluntary: Firm initiated · Letter
Get an email if BUPRENORPHINE HYDROCHLORIDE has another recall
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Brand
- BUPRENORPHINE HYDROCHLORIDE
- Manufacturer
- PAR Sterile Products LLC
- Distributor
- Nationwide in the USA
- Lot
- Lot #: 821102, 821103, Exp 01/18; 821104, 821106, 821107, Exp 02/18; 821108, Exp 03/18; 821884, 821885, Exp 07/18; 821886, 821887, Exp 08/18; 822767, Exp 09/18; 824183, Exp 10/18.
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDABuprenorphine Hydrochloride, Injection 0.3 mg/mL, Rx Only, 5 x 1 mL Single Dose Vials, Manufactured for: EndoOctober 7, 2026
- FDABuprenorphine HCl, CIII, Injection, 0.3 mg/mL, 5 x 1 mL Single Dose Vials per Carton, Rx Only, ForJune 24, 2026
- FDABuprenorphine Hydrochloride, Injection, 0.3mg/mL, 5x1 mL Single Dose Vials, Rx only, Manufactured for: EndoMay 20, 2026
- FDABuprenorphine Hydrochloride Injection, 0.3 mg base/mL, 1 mL Single-dose Carpuject, Sterile Cartridge Unit withJuly 3, 2024
- FDAIC-Green (indocyanine green for injection, USP), 25 mg, packaged in a kit containing six vials of 25 mgMay 17, 2017
- FDAOlanzapine Tablets, 2.5 mg, 1000-count bottles, Rx Only, Distributed by: Sun Pharmaceutical Industries, Inc.,May 17, 2017
Questions about this recall
Was Buprenorphine HCI Injection, 0.3 mg/mL, 1 mL Single Dose Vial (NDC 42023-179-01), packaged in 1 mL x 5 Single Dose Vials per carton (NDC 42023-179-05), Rx Only, Distributed by: Par Pharmaceuticals Companies, Inc., Spring Valley, NY 10977. recalled?
Yes. FDA published recall D-0698-2017 on May 17, 2017. Reported hazard: Crystallization: due to the presence of white, crystalline particulates, adhered to the side and bottom of the glass vials, which are comprised of principally dextrose and the buprenorphine active component.
What should I do if I have this product?
Voluntary: Firm initiated · Letter
How do I know if my unit is part of the recall?
Compare your product details with the notice. Brand: BUPRENORPHINE HYDROCHLORIDE.